Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has released a clinical-stage program update and noted upcoming milestones for its development pipeline. Those milestones for CYB003, the company’s deuterated psilocybin analog program, include the completion of phase 2 topline safety and efficacy data readout for CYB003 in MDD and submitting topline data to U.S. Food and Drug Administration for an end of phase 2 meeting in early 2024. For the company’s deuterated DMT program, highlights include phase 1 dosing, pharmacokinetic (“PK”) and pharmacodynamic (“PD”), and safety data for CYB004 and SPL028 coming in Q4 2023 along with the initiation of phase 2 proof-of-concept study in participants with generalized anxiety disorder, a CYB004 subcutaneous formulation study and SPL028 formulation work, all slated for Q1 2024.
“The clinical progress we have made over the past few months is truly remarkable, exemplified by our recently released positive phase 2 interim data for CYB003 in major depressive disorder (‘MDD’), which demonstrated rapid and significant improvement in depression symptoms three weeks after a single dose,” said Cybin CEO Doug Drysdale in the press release. “In coming months, we look forward to presenting the complete phase 2 topline data for CYB003 in MDD, as well as phase 1 data readouts for our proprietary novel deuterated N,N-dimethyltryptamine (‘DMT’) compounds, CYB004 and SPL028. Looking ahead, Cybin plans to run four clinical studies in 2024, reflecting the team’s strong execution on strategic priorities and commitment to accelerating our programs. We are in an exciting period of clinical development, and we look forward to sharing important data readouts across our pipeline of differentiated therapeutics.”
To view the full press release, visit https://ibn.fm/wMcw2
About Cybin Inc.
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental-health conditions. Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug-discovery platforms, innovative drug-delivery systems, and novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder; the company also has a research pipeline of investigational psychedelic-based compounds. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
InvestorWire is powered by IBN